Bicycle Therapeutics PLC expected to post a loss of 95 cents a share - Earnings Preview

Bicycle Therapeutics

01/08/2025 14:19

Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The Cambridge Cambridgeshire-based  company is expected to report a 6.9% decrease in revenue to $8.714 million from $9.36 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Bicycle Therapeutics PLC is for a loss of 95 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $24.50, about 65.2% above its last closing price of $8.52

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.82
-0.84
-0.88
Missed
-4.5
Dec. 31 2025
-0.82
-0.86
-0.82
Beat
4.5
Sep. 30 2024
-0.75
-0.78
-0.74
Beat
5.3​
Jun. 30 2024
-1.06
-1.10
-0.77
Beat
29.9
​​Mar. 31 2024
-1.25
-1.24
-0.62
Beat
50.1
Dec. 31 2023
-1.17
-1.23
-1.16
Beat
6​
Sep. 30 2023
-1.16
-1.17
-1.26
Missed
-7.6
Jun. 30 2023
-1.31
-1.29
-1.41
Missed
-9

This summary was machine generated August 1 at 13:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)